Cutia Therapeutics (HK:2487) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics has reported a remarkable revenue surge of approximately 129.9% for the first nine months of 2024, reaching RMB148.9 million. This growth highlights the strong market performance of its commercialized products, signaling potential opportunities for investors. However, the company advises caution as these figures are based on preliminary unaudited data.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.